Three-dimensional conformal radiotherapy and dose escalation: Where do we stand?

被引：64

作者：

Zelefsky, MJ

Leibel, SA

Kutcher, GJ

Fuks, Z

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA

来源：

SEMINARS IN RADIATION ONCOLOGY | 1998年 / 8卷 / 02期

关键词：

D O I：

10.1016/S1053-4296(98)80006-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：107 / 114

页数：8

共 35 条

[31] The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformal radiotherapy [J].

Zelefsky, MJ ;

Happersett, L ;

Leibel, SA ;

Burman, CM ;

Schwartz, L ;

Dicker, AP ;

Kutcher, GJ ;

Fuks, Z .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (01) :13-19

[32] NEOADJUVANT HORMONAL-THERAPY IMPROVES THE THERAPEUTIC RATIO IN PATIENTS WITH BULKY PROSTATIC-CANCER TREATED WITH 3-DIMENSIONAL CONFORMAL RADIATION-THERAPY [J].

ZELEFSKY, MJ ;

LEIBEL, SA ;

BURMAN, CM ;

KUTCHER, GJ ;

HARRISON, A ;

HAPPERSETT, L ;

FUKS, Z .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 29 (04) :755-761

[33] Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy [J].

Zelefsky, MJ ;

Harrison, A .

UROLOGY, 1997, 49 (3A) :38-45

[34]

ZELEFSKY MJ, 1995, CANCER J SCI AM, V1, P42

[35]

ZELEFSKY MJ, IN PRESS INT J RAD O

← 1 2 3 4 →